Results 231 to 240 of about 801,078 (341)

A multipart phase 1 study of the safety, pharmacodynamics and pharmacokinetics of ALG‐055009, a novel thyroid hormone receptor beta (THR‐β) agonist for metabolic dysfunction‐associated steatohepatitis (MASH), in healthy participants

Clinical Pharmacology in Drug Development, EarlyView.
Abstract ALG–055009 is an oral thyroid hormone receptor beta (THR‐β) agonist being evaluated for treating metabolic dysfunction–associated steatohepatitis (MASH). This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALG‐055009 and bioavailability/food effect.
Hakim Charfi, Benedetta Massetto, Megan Fitzgerald, Kha Le, Stanley Wang, Ifong Kan‐Eng, Meenakshi Venkatraman, Naqvi Mohammad, Lawrence Blatt, Tse‐I Lin, Sushmita M. Chanda, John Fry   +11 more
wiley   +1 more source

Comparative Efficacy of Digital Flexible Ureteroscopy in Management of Renal Stones in Normal-Weight and Overweight/Obese Patients. [PDF]

Res Rep Urol
Thanh NH, Tuan NM, Long H, Khanh TQ, Cuong NX, Giang NT, Vinh NT, Minh DN, Dinh DA.   +8 more
europepmc   +1 more source

The Epidemiologic Study to Reasses “Overweight” in 15year-old Students

, 1997
高須 好美, 関 正己, 鈴木 逸夫, 水野 宣博, 生川 優, 新美 泰司, 川端 光, 吉田 之彦, 栗田 正三, 伊藤 寿高, 近藤 康明, 伊藤 春人, 稲石 友彦, 石黒 利彦, 石崎 満, 高田 和夫, 岩田 豊   +16 more
openalex   +2 more sources

Dietary sodium intake and incidence of congestive heart failure in overweight U.S. men and women: NHANES I epidemiologic follow-up study (NHEFS) [PDF]

, 2000
Hongru Jiang
openalex   +1 more source

A Pharmacometric Method for Quantitative Determination of Improvement in Body Composition and Characterization of the Exposure–Response Relationship during Treatment of Obesity with Tirzepatide

Clinical Pharmacology &Therapeutics, EarlyView.
About half of the world's population is living with overweight or obesity. Tirzepatide is an approved treatment for chronic weight management. We sought to characterize the exposure–response relationship for weight reduction in patients with overweight or obesity and quantify the associated changes in body composition.
Emmanuel Chigutsa, Lucy Her, Xiaosu Ma, Shweta Urva, Karen Schneck   +4 more
wiley   +1 more source

Association of overweight with treatment outcomes in pulmonary tuberculosis. [PDF]

BMC Infect Dis
Kim KH, Kim HW, Lee EG, Park Y, Jung SS, Kim JW, Oh JY, Lee H, Kim SH, Kim SH, Lyu J, Ko Y, Kwon SJ, Jeong YJ, Kim DJ, Koo HK, Chae G, Kyung SY, Lee SS, Park JS, Jeong Y, Kim JS, Min J.   +22 more
europepmc   +1 more source

SERTRALINE, A SELECTIVE SEROTONIN RE-UPTAKE INHIBITOR, RESULTS IN WEIGHT LOSS AND AN INCREASED 24-HOUR ENERGY EXPENDITURE IN TRAINED AND UNTRAINED OVERWEIGHT WOMEN 515

, 1996
Karly M. Murphy, Caron B. Jander, Shelly Meltzer, Mike Lambert, Anh Tuyet Bui Lee, Timothy D. Noakes, Estelle V. Lambert   +6 more
openalex   +1 more source

Conjugated Linoleic Acid Reduces Body Fat Mass in Overweight and Obese Humans [PDF]

, 2000
Ola Gudmundsen, Henrietta Blankson, J. A. Stakkestad, Hans Fagertun, E Thom, Jan Wadstein   +5 more
openalex   +1 more source

Re‐Evaluation of Fixed Dosing Versus Body Size‐Based Dosing Approaches for Large Molecule Therapeutics in Adults

Clinical Pharmacology &Therapeutics, EarlyView.
Wang et al.1 (2009) and Zhang et al.2 (2011) recommended a fixed dosing approach for large molecule therapeutics for first‐in‐human (FIH) trials, based on the finding that the majority of α values (body size effect on clearance) were < 0.5 across 12 monoclonal antibodies (mAbs) and 18 therapeutic proteins (TPs) and peptides, and fixed dosing provides ...
Andrew B. SyBing, Huili Chen, Diane D. Wang   +2 more
wiley   +1 more source

The obesity paradox revisited - influence on the results of percutaneous coronary interventions. [PDF]

AsiaIntervention
Movahed MR, Nathan A, Hashemzadeh M.
europepmc   +1 more source